Jan 9 (Reuters) - Kubota Pharmaceutical Holdings Co Ltd
* Says coâ€™s wholly owned unit Acucela Inc signed a two-year development agreement with gene delivery expert SIRION Biotech GmbH (SIRION) to establish optimized AAV vectors for clinical applications in ocular gene therapy
* Says Acucela bolsters its move into the fast growing gene therapy market to find a genetic cure for retinitis pigmentosa
* Key terms of the agreement include milestone payments to SIRION, with additional royalties to be paid on net sales from resulting products or therapies
Source text in Japanese: goo.gl/n8VbQu
Further company coverage: (Beijing Headline News)
 